Xcout Intel
4DMEDICAL LIMITED
4DMedical Ltd is an Australian medical technology company based in Melbourne, Victoria, specializing in respiratory imaging and software solutions.
Subscribe to see 4DMEDICAL LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
4DMEDICAL LIMITED at a glance
4DMEDICAL LIMITED is a health care equipment & services company headquartered in Carlton, Australia. It is publicly listed (4DX) with a market capitalisation of $1.6B. Xcout tracks 20 named people at 4DMEDICAL LIMITED, including Andreas Fouras, PhD (Managing Director & CEO).
4DMEDICAL LIMITED leadership
- Andreas Fouras, PhDManaging Director & CEO
- Julian SuttonChief Financial Officer
- Greg Mogel, MD, FACRChief Medical Officer
- Matt TuckerChief Commercial Officer
- Aidan Jamison, PhDSVP, Engineering
- David HannesSVP, Global Business Development
14 more named people on record for 4DMEDICAL LIMITED, with roles, board committees and tenure — see the full roster →
4DMEDICAL LIMITED competitors
A few of 4DMEDICAL LIMITED's closest competitors — see the full list of competitors and alternatives →
CurveBeam AI Ltd combines point-of-care diagnostic cone beam computed tomography imaging systems with specialized medical software and diagnostics, with its corporate office located in Melbourne, Australia.
EMVision Medical Devices Limited is an Australian enterprise specializing in the innovation, development, and market introduction of advanced imaging and diagnostic healthcare technologies. The company's principal offering is a compact, mobile brain scanner engineered for the swift detection and continuous tracking of strokes, in addition to fulfilling other medical imaging necessities. Founded in 2017, its operations are headquartered in Macquarie Park.
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle East, and Africa. Its portfolio of non-invasive, MRI-based diagnostic tools includes FerriScan, a system for quantifying liver iron concentration (LIC); FerriSmart, leveraging artificial intelligence (AI) for automated, real-time assessment of LIC; HepaFat-AI, an AI-driven solution for real-time, multi-metric liver fat quantification; CardiacT2, which provides dual analysis in conjunction with FerriScan to evaluate cardiac iron accumulation; HepaFat-Scan, a non-invasive MRI method for assessing liver fat within tissue; and LiverSmart, a comprehensive non-invasive MRI device integrating FerriSmart and HepaFat-AI for a unified report. The company further extends its offerings to include quantitative imaging measurements and Contract Research Organization (CRO) services, encompassing rigorous image analysis, imaging charter development, robust project and data management, proactive issue resolution, site tracking with clinical trial progress reports, and streamlined data flow coordination. They also provide comprehensive biomarker services, covering analysis of blood, urine, and protein analytes, alongside RNA, DNA, and genotyping. Their support for multinational and multicenter clinical trials extends to protocol development, subject inclusion/exclusion criteria assessment, dose modification strategies, new therapy safety profile evaluations, and establishing primary and secondary endpoints for drug efficacy. Additionally, they supply phantoms crucial for MRI machine calibration. Its client base includes clinicians, who utilize their solutions for managing human diseases, and pharmaceutical and therapeutic companies engaged in clinical research. Established in 1987, Resonance Health Limited maintains its headquarters in Burswood, Australia.
Optiscan Imaging Limited specializes in the development and market introduction of confocal microscopy technology, applied across both clinical and pre-clinical settings in Australia, Germany, and other global regions. A notable offering is the FIVE2 (ViewnVivo) system, a compact confocal endomicroscope utilized for a broad range of research, including clinical, translational, and pre-clinical studies. Additionally, the company is actively developing the InVivage device, which is intended for use in cancer screening and surgical procedures. Established in 1994, Optiscan Imaging Limited maintains its headquarters in Mulgrave, Australia.
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
Get 4DMEDICAL LIMITED's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on 4DMEDICAL LIMITED in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access